Pharmaron Beijing Co Ltd
SZSE:300759

Watchlist Manager
Pharmaron Beijing Co Ltd Logo
Pharmaron Beijing Co Ltd
SZSE:300759
Watchlist
Price: 26.72 CNY -5.85% Market Closed
Market Cap: 39.7B CNY
Have any thoughts about
Pharmaron Beijing Co Ltd?
Write Note

Income Statement

Earnings Waterfall
Pharmaron Beijing Co Ltd

Revenue
11.5B CNY
Cost of Revenue
-7.7B CNY
Gross Profit
3.8B CNY
Operating Expenses
-2.3B CNY
Operating Income
1.6B CNY
Other Expenses
355.7m CNY
Net Income
1.9B CNY

Income Statement
Pharmaron Beijing Co Ltd

Rotate your device to view
Income Statement
Currency: CNY
Sep-2018 Dec-2018 Mar-2019 Jun-2019 Sep-2019 Dec-2019 Mar-2020 Jun-2020 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023 Dec-2023 Mar-2024 Jun-2024
Revenue
Revenue
2 713
N/A
2 908
+7%
3 089
+6%
3 274
+6%
3 499
+7%
3 757
+7%
3 953
+5%
4 314
+9%
4 717
+9%
5 134
+9%
5 664
+10%
6 226
+10%
6 849
+10%
7 444
+9%
8 057
+8%
8 793
+9%
9 545
+9%
10 266
+8%
10 887
+6%
11 272
+4%
11 424
+1%
11 538
+1%
11 485
0%
11 502
+0%
Gross Profit
Cost of Revenue
(1 878)
(1 958)
(2 110)
(2 229)
(2 349)
(2 424)
(2 582)
(2 737)
(2 943)
(3 215)
(3 577)
(3 945)
(4 382)
(4 768)
(5 249)
(5 739)
(6 164)
(6 502)
(6 909)
(7 152)
(7 355)
(7 422)
(7 558)
(7 658)
Gross Profit
836
N/A
950
+14%
979
+3%
1 046
+7%
1 151
+10%
1 333
+16%
1 371
+3%
1 577
+15%
1 774
+12%
1 919
+8%
2 087
+9%
2 281
+9%
2 467
+8%
2 676
+8%
2 808
+5%
3 054
+9%
3 381
+11%
3 764
+11%
3 978
+6%
4 120
+4%
4 069
-1%
4 116
+1%
3 926
-5%
3 844
-2%
Operating Income
Operating Expenses
(430)
(500)
(508)
(529)
(562)
(627)
(638)
(679)
(719)
(832)
(878)
(935)
(1 059)
(1 166)
(1 258)
(1 473)
(1 697)
(2 042)
(2 141)
(2 264)
(2 285)
(2 331)
(2 256)
(2 272)
Selling, General & Administrative
(389)
(432)
(486)
(502)
(535)
(541)
(606)
(653)
(691)
(720)
(819)
(857)
(954)
(978)
(1 146)
(1 353)
(1 532)
(1 641)
(1 886)
(1 949)
(1 965)
(1 767)
(1 879)
(1 890)
Research & Development
(24)
(25)
(34)
(44)
(51)
(54)
(75)
(79)
(89)
(91)
(114)
(127)
(146)
(135)
(162)
(171)
(219)
(261)
(320)
(381)
(402)
(419)
(465)
(474)
Depreciation & Amortization
0
(62)
0
0
0
(73)
0
0
0
(88)
0
0
0
(116)
0
0
0
(196)
0
0
0
(241)
0
0
Other Operating Expenses
(17)
19
12
17
24
42
44
53
61
67
54
49
41
63
50
50
55
56
65
66
82
96
87
92
Operating Income
406
N/A
450
+11%
471
+5%
516
+10%
589
+14%
707
+20%
733
+4%
898
+22%
1 055
+18%
1 087
+3%
1 209
+11%
1 346
+11%
1 408
+5%
1 510
+7%
1 550
+3%
1 580
+2%
1 684
+7%
1 723
+2%
1 838
+7%
1 856
+1%
1 784
-4%
1 785
+0%
1 670
-6%
1 573
-6%
Pre-Tax Income
Interest Income Expense
(59)
(55)
(59)
(69)
(75)
(75)
(35)
95
108
244
286
119
231
405
403
414
249
(277)
(36)
(0)
11
14
35
611
Non-Reccuring Items
(1)
(2)
(2)
(2)
(2)
(1)
(1)
(1)
(1)
(7)
(7)
(8)
(8)
(1)
(1)
(1)
(2)
244
(1)
(1)
0
48
(20)
(21)
Total Other Income
15
0
(2)
(3)
(7)
1
(14)
(14)
(14)
(5)
(1)
(4)
(3)
(3)
(7)
(6)
(15)
(24)
(25)
(23)
(16)
(10)
(5)
(7)
Pre-Tax Income
360
N/A
393
+9%
409
+4%
443
+8%
505
+14%
633
+25%
684
+8%
978
+43%
1 148
+17%
1 319
+15%
1 487
+13%
1 453
-2%
1 629
+12%
1 911
+17%
1 945
+2%
1 988
+2%
1 916
-4%
1 666
-13%
1 777
+7%
1 832
+3%
1 780
-3%
1 838
+3%
1 680
-9%
2 156
+28%
Net Income
Tax Provision
(61)
(60)
(63)
(69)
(79)
(102)
(112)
(138)
(169)
(172)
(197)
(225)
(244)
(291)
(324)
(350)
(356)
(314)
(311)
(261)
(237)
(256)
(232)
(276)
Income from Continuing Operations
300
333
345
373
426
531
572
841
980
1 147
1 291
1 228
1 385
1 620
1 620
1 638
1 560
1 352
1 465
1 571
1 542
1 582
1 448
1 881
Income to Minority Interest
0
0
1
5
11
17
23
24
28
25
26
31
39
41
44
44
22
22
8
4
10
19
36
48
Net Income (Common)
300
N/A
333
+11%
346
+4%
378
+9%
437
+16%
547
+25%
595
+9%
865
+45%
1 008
+17%
1 172
+16%
1 317
+12%
1 258
-4%
1 423
+13%
1 661
+17%
1 664
+0%
1 682
+1%
1 582
-6%
1 375
-13%
1 474
+7%
1 575
+7%
1 553
-1%
1 601
+3%
1 483
-7%
1 928
+30%
EPS (Diluted)
0.51
N/A
0.56
+10%
0.54
-4%
0.57
+6%
0.68
+19%
0.83
+22%
0.75
-10%
1.09
+45%
1.27
+17%
1.48
+17%
1.66
+12%
1.05
-37%
1.19
+13%
0.91
-24%
1.4
+54%
1.41
+1%
0.89
-37%
0.77
-13%
0.83
+8%
2.69
+224%
0.87
-68%
0.9
+3%
0.83
-8%
1.09
+31%

See Also

Discover More